Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results

Andrea Lombardi1,2, Giorgio Bozzi1, Riccardo Ungaro1, Simone Villa3, Valeria Castelli1, Davide Mangioni1, Antonio Muscatello1, Andrea Gorii1,2,3 and Alessandra Bandera1,2,*

Background: BNT162b2 and mRNA-1273 are the two recently approved mRNA-based vaccines against COVID-19 which has shown excellent safety and efficacy. Preliminary data about specific and neutralizing antibodies is available covering the first 100 days after vaccination.

Methods: We reviewed all the publications regarding the immunologic consequences of BNT162b2 and mRNA-1273 vaccination. A summary of specific antibodies concentration and neutralizing antibodies titers elicited by each vaccine is provided.

Results: BNT162b2 and mRNA-1273 displayed a reassuring safety and efficacy profile, with the latter above 94%. They can elicit specific antibodies titers and neutralizing antibodies concentrations that are far superior from those observed among COVID-19 human convalescent serum, across a wide span of age, for at least 100 days after vaccination. Moreover, the vaccine-induced T cellular response is oriented toward a T\(_{H1}\) response and no evidence of vaccine-enhanced disease have been reported.

Discussion: BNT162b2 and mRNA-1273 can elicit specific antibodies titers and neutralizing antibodies concentrations above those observed among COVID-19 human convalescent serum in the first 100 days after vaccination. Data about vaccine efficacy in those with previous COVID-19 or immunocompromised is still limited.

Keywords: COVID-19, SARS-CoV-2, RNA vaccine, CTL, antibodies, neutralization test

INTRODUCTION

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the beta-coronavirus responsible for the disease called Coronavirus Disease 2019 (COVID-19). Currently, SARS-CoV-2 has infected over 75 million people and has caused 1.6 million deaths (1). To date, no specific therapies are available. Mass prophylactic vaccination is probably the only viable path to cost-effectively curb out the pandemic.

The ability of humoral and cellular immunity to protect from SARS-CoV-2 has been clearly demonstrated. In rhesus macaques the adoptive transfer of purified IgG from convalescent to naïve animals protected the latter from SARS-CoV-2 challenge in a dose dependent fashion. The
depletion of T CD8+ cell from convalescent macaques partially abrogated the protective efficacy of natural immunity against SARS-CoV-2 re-challenge, suggesting the importance of cellular immunity (2). In humans, a study conducted on healthcare professionals, showed how the presence of anti-spike or anti-nucleocapsid antibodies was associated with a significant reduction in the risk of reinfection throughout an observation period of over 6 months (3).

Less clear is the duration of the protection provided by a previous infection. Most long-term studies performed in patients with either Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) or Middle East respiratory syndrome coronavirus (MERS-CoV) infection, found that IgG titers waned over time (typically remaining detectable up to at least a year), while others found detectable levels of IgG up to 3 years after symptom onset (4). Despite this apparent decline of specific IgG, long-lasting memory T cells reactive to the nucleocapsid protein of SARS-CoV were found in individual 17 years after the infection, suggesting that beta-coronaviruses infection can induce long-lasting T cell immunity (5). In COVID-19, kinetics of the neutralizing antibody response is typical of an acute viral infection, with declining neutralizing antibody titers observed after an initial peak, which depends on disease severity (6). Recently, it has been estimated that it takes at least 372, 416, and 133 days for plaque reduction neutralization assays with 50% end-point (PRNT50) titers to drop to the detection limit for severe, mild and asymptomatic patients, respectively (7). High expectations are therefore placed on vaccines, for both the immunization of naïve population and eventually the boosting of already achieved immunity among previously infected patients.

In this review, we describe the immunologic effects of BNT162b2 or mRNA-1273 vaccines, updating with the results of phase III trials of mRNA vaccines the superb paper of Krammer (8). A summary of specific antibodies concentration (Table 1) and neutralizing antibodies (NA) titers (Table 2) elicited by each vaccine is provided, with stratification per age of the participants, dose administered, and relative ratio compared to values detected in human COVID-19 convalescent serum (HCS). We also discuss the role of these vaccines among special populations and the evidence available on the feared vaccine-enhanced immune response.

**THE INNOVATION OF RNA VACCINES**

The first experiments on RNA inoculation in animal models date back to the 1990s (15). However, before COVID-19, no RNA-based vaccine has never been approved or remarkable progresses have been made in their use in clinical trials.

The concept behind the use of RNA—either self-replicating or not—, namely a messenger RNA (mRNA), is simple: inoculate a molecule (i.e., the RNA) carrying the genetic information coding for the antigen, which will be produced via the ribosomal machineries of the host cells, rather than injecting the antigen itself to trigger the immune response.

Since the start of the COVID-19 pandemic, besides RNA vaccines, several “next-generation” vaccine platforms have been employed, like: viral vectors, DNA vaccine, and antigen-presenting cells (16). To date, only two non-self-replicating mRNA vaccine against COVID-19 have been conditionally approved by independent regulatory agencies.

**BNT162B2 (PFIZER/BIONTECH)**

BNT162b2 was the first vaccine to be granted a conditional marketing approval by the European Medicines Agency (EMA) for the prevention of COVID-19 (17). BNT162b2 is administered intramuscularly after dilution as a cycle of 2 doses (0.3 mL each, containing 30 µg of COVID-19 mRNA vaccine embedded in lipid nanoparticles), 21 days apart (18). BNT162b2 consists of a nucleoside-modified RNA, contained within a lipid nanoparticle, which encodes the SARS-CoV-2 full-length spike, modified by two proline mutations to lock it in the prefusion conformation (10). In the initial phases of drug development, a similar product was concomitantly assessed, BNT162b1, which encodes the SARS-CoV-2 receptor-binding domain (RBD) (10). BNT162b1 is not anchored on the membrane like BNT162b2 but instead secreted.

Preclinical data investigated BNT162b2 immunogenicity and anti-viral properties in mice and non-human primates. Immunization of mice with a single dose of BNT162b2 induced dose level-dependent increases in pseudovirus neutralization titers. Prime-boost vaccination of rhesus macaques elicited authentic SARS-CoV-2 neutralizing geometric mean titers 10.2 to 18.0 times that from SARS-CoV-2 HCS. From the cellular point of view, BNT162b2 generated strong Th1 type CD4+ and IFNγ+ CD8+ T-cell responses in both mice and rhesus macaques. Finally, the BNT162b2 vaccine candidate fully protected the lungs of immunized rhesus macaques from infectious SARS-CoV-2 challenge (19).

In a Phase I/II study (NCT04368728) conducted among 45 adult participants with 18–55 years of age, BNT162b1 was administered at doses of 10 or 30 µg in two administrations 21 days apart (9). Twelve participants received a single 100 µg dose at day 1 and other 9 participants received placebo. Robust immunogenicity was documented with all vaccine doses. By 21 days after the first dose, geometric mean concentrations (GMCS) of RBD-binding IgG ranged from 534 to 1,778 U·mL−1 compared to a value of 602 U·mL−1 observed in a panel of 38 HCS drawn at least 14 days after a PCR-confirmed diagnosis. Seven days after administration of the second dose, with 10 or 30 µg of BNT162b1, the GMC of RBD-binding IgG was ~8.0–50 times higher the GMC of HCS and remained far superior also at the last evaluation performed, 14 days after the second dose. This higher vaccine-induced GMC of RBD-binding IgG compared to GMC of HCS can be attributed, in part, to epitope-binding antibodies that are exposed to the RBD immunogen expressed after vaccination but are inaccessible to antibodies in RBDSs that are embedded in the tips of SARS-CoV-2 virions during the infection. Regarding the geometric mean titer (GMT) of NA this, after the second dose of 10 and 30 µg was, respectively, 1.8 and 2.8 times the GMT of the serum panel from HCS. At day 35 (ie.,14 days after the second dose), the GMT of NA had increased, up
| Vaccine | Dose (µg) | Age group (years) | Participants | Days after vaccine first dose | Titer IgG vaccinated | Ratio | Titer IgG HCS | Reference |
|---------|-----------|-------------------|--------------|-------------------------------|---------------------|-------|---------------|-----------|
| BNT162b1* | 10 | 19–54 | 12 | 7 | 0.9 | 0.00 | 602 | (9) |
| | | | | 21 | 534 | 0.89 |
| | | | | 28 | 4,813 | 8.00 |
| | | | | 35 | 5,880 | 9.77 |
| | 30 | 19–54 | 12 | 7 | 0.8 | 0.00 |
| | | | | 21 | 1,536 | 2.55 |
| | | | | 28 | 27,872 | 46.30 |
| | | | | 35 | 16,166 | 26.85 |
| | 100 | 19–54 | 12 | 7 | 1.2 | 0.00 |
| | | | | 21 | 1,778 | 2.95 |
| | | | | 28 | 1,260 | 2.09 |
| BNT162b1† | 10 | 18–55 | 12 | 21 | 294 | 0.47 | 631 | (10) |
| | | | | 28 | 3,868 | 6.13 |
| | | | | 35 | 5,120 | 8.11 |
| | 20 | 18–55 | 12 | 21 | 204 | 0.32 |
| | | | | 28 | 3,243 | 5.14 |
| | | | | 35 | 7,480 | 11.85 |
| | 30 | 18–55 | 12 | 21 | 853 | 1.35 |
| | | | | 28 | 23,516 | 37.27 |
| | | | | 35 | 13,940 | 22.09 |
| | 10 | 65–85 | 12 | 21 | 36 | 0.06 |
| | | | | 28 | 980 | 1.55 |
| | | | | 35 | 1,527 | 2.42 |
| | 20 | 65–85 | 12 | 21 | 125 | 0.20 |
| | | | | 28 | 10,623 | 16.84 |
| | | | | 35 | 6,399 | 10.14 |
| | 30 | 65–85 | 12 | 21 | 86 | 0.14 |
| | | | | 28 | 6,580 | 10.43 |
| | | | | 35 | 4,798 | 7.60 |
| BNT162b2† | 10 | 18–55 | 12 | 21 | 612 | 0.97 |
| | | | | 28 | 5,782 | 9.16 |
| | | | | 35 | 4,717 | 7.48 |
| | 20 | 18–55 | 12 | 21 | 547 | 0.87 |
| | | | | 28 | 12,464 | 19.75 |
| | | | | 35 | 7,367 | 11.68 |
| | 30 | 18–55 | 12 | 21 | 1,265 | 2.00 |
| | | | | 28 | 9,136 | 14.48 |
| | | | | 35 | 8,147 | 12.91 |
| | 10 | 65–85 | 12 | 21 | 172 | 0.27 |
| | | | | 28 | 3,203 | 5.08 |
| | | | | 35 | 3,560 | 5.64 |
| | 20 | 65–85 | 12 | 21 | 81 | 0.13 |
| | | | | 28 | 3,056 | 4.84 |
| | | | | 35 | 2,656 | 4.21 |
| | 30 | 65–85 | 12 | 21 | 329 | 0.52 |
| | | | | 28 | 7,985 | 12.65 |
| | | | | 35 | 6,014 | 9.53 |
| BNT162b1* | 1 | 20–56 | 12 | 8 | 3 | 0.00 | 602 | (11) |
| | | | | 22 | 265 | 0.44 |
| | | | | 29 | 2,015 | 3.35 |

(Continued)
TABLE 1  |  Continued

| Vaccine          | Dose (µg) | Age group (years) | Participants | Days after vaccine first dose | Titer IgG vaccinated | Ratio   | Titer IgG HCS | Reference |
|------------------|-----------|-------------------|--------------|------------------------------|---------------------|---------|---------------|-----------|
| mRNA-1273        | 10        | 20–56             | 12           | 43                           | 3,920               | 6.51    |               |           |
|                  |           |                   |              | 8                            | 1                   | 0.00    |               |           |
|                  |           |                   |              | 22                           | 826                 | 1.37    |               |           |
|                  |           |                   |              | 29                           | 9,107               | 15.13   |               |           |
|                  |           |                   |              | 43                           | 6,707               | 11.14   |               |           |
|                  | 30        | 20–56             | 12           | 8                            | 2                   | 0.00    |               |           |
|                  |           |                   |              | 22                           | 1,273               | 2.11    |               |           |
|                  |           |                   |              | 29                           | 17,051              | 28.32   |               |           |
|                  |           |                   |              | 43                           | 12,431              | 20.65   |               |           |
|                  | 50        | 20–56             | 12           | 8                            | 1                   | 0.00    |               |           |
|                  |           |                   |              | 22                           | 1,672               | 2.78    |               |           |
|                  |           |                   |              | 29                           | 25,006              | 41.54   |               |           |
|                  |           |                   |              | 43                           | 18,289              | 30.38   |               |           |
|                  | 60        | 20–56             | 12           | 8                            | 1                   | 0.00    |               |           |
| mRNA-1273        | 25        | 18–55             | 15           | 1                            | 0.5                 | 0.00    |               |           |
|                  |           |                   |              | 15                           | 5,674               | 0.40    |               |           |
|                  |           |                   |              | 29                           | 8,304               | 0.58    |               |           |
|                  |           |                   |              | 36                           | 94,998              | 6.69    |               |           |
|                  |           |                   |              | 43                           | 91,081              | 6.42    |               |           |
|                  |           |                   |              | 57                           | 77,904              | 5.49    |               |           |
|                  | 100       | 18–55             | 15           | 1                            | 1.3                 | 0.00    |               |           |
|                  |           |                   |              | 15                           | 19,068              | 1.34    |               |           |
|                  |           |                   |              | 29                           | 20,525              | 1.45    |               |           |
|                  |           |                   |              | 36                           | 213,076             | 15.01   |               |           |
|                  |           |                   |              | 43                           | 221,956             | 15.64   |               |           |
|                  |           |                   |              | 57                           | 147,332             | 10.38   |               |           |
| mRNA-1273        | 250       | 18–55             | 15           | 1                            | 1.4                 | 0.00    |               |           |
|                  |           |                   |              | 15                           | 30,641              | 2.16    |               |           |
|                  |           |                   |              | 29                           | 38,448              | 2.71    |               |           |
|                  |           |                   |              | 36                           | 315,723             | 22.24   |               |           |
|                  |           |                   |              | 43                           | 254,374             | 17.92   |               |           |
|                  |           |                   |              | 57                           | 215,140             | 15.15   |               |           |
| mRNA-1273        | 25        | 56–70             | 10           | 1                            | 189                 | 0.00    | 138,901       | (13, 14) |
|                  |           |                   |              | 15                           | 10,509              | 0.08    |               |           |
|                  |           |                   |              | 29                           | 17,884              | 0.13    |               |           |
|                  |           |                   |              | 36                           | 313,720             | 2.26    |               |           |
|                  |           |                   |              | 43                           | 476,136             | 3.43    |               |           |
|                  |           |                   |              | 57                           | 323,945             | 2.33    |               |           |
|                  | 100       | 56–70             | 10           | 1                            | 111                 | 0.00    |               |           |
|                  |           |                   |              | 15                           | 14,837              | 0.11    |               |           |
|                  |           |                   |              | 29                           | 57,986              | 0.42    |               |           |
|                  |           |                   |              | 36                           | 480,094             | 3.31    |               |           |
|                  |           |                   |              | 43                           | 303,630             | 2.19    |               |           |
|                  |           |                   |              | 57                           | 1,128,391           | 8.12    |               |           |
| 25               | 71        | 10                |              | 1                            | 655                 | 0.00    |               |           |
|                  |           |                   |              | 15                           | 55,532              | 0.40    |               |           |
|                  |           |                   |              | 29                           | 115,831             | 0.83    |               |           |

(Continued)
to 1.9 and 4.6-fold the GMT of the HCS, for the 10 and 30 µg doses, respectively. This is consistent with the antibody affinity maturation process.

Comparable results were obtained in a second placebo-controlled, observer-blinded, dose-escalation, phase 1 trial (NCT04368728), which compared the safety and immunogenicity of BNT162b1 and BNT162b2 among 195 adults aged 18–55 or 65–85 years (10). In all groups but one, participants received two doses (10, 20, or 30 µg), with a 21-day interval between doses; in one group (100 µg of BNT162b1), participants received one dose. The 50% neutralizing GMTs for the two vaccines, on day 28 or 35, was between 1.7 and 4.6 times the GMT of the HCS among participants aged 18–55 years and 1.1–2.2 times the GMT of HCS among subjects aged 65–85. Immunogenicity was reduced in those older than 65 years of age compared to younger participants but remained relevant. Overall, BNT162b2 was associated with a lower incidence and severity of systemic reactions than BNT162b1, particularly in older adults, and therefore was chosen for advancing to phase II/III studies.

Clearly, the mere ability to generate specific antibodies for the epitope encoded by the vaccine alone is not indicative of efficacy in protecting against SARS-CoV-2 infection. Therefore, the efficacy and safety of BNT162b2 were verified in a large multinational, placebo-controlled, observer-blinded, efficacy trial (NCT04368728) which involved 43,548 participants (10). Regarding efficacy, in participants without evidence of previous infection, eight cases of COVID-19 were recorded starting 7 days after the administration of the second dose among vaccinated and 162 cases among those who had received the placebo. Overall, BNT162b2 showed 95% efficacy [95% credible interval (CI), 90.3 to 97.6] in preventing COVID-19. It is interesting to note that between first and second dose, 39 cases of COVID-19 were observed in the BNT162b2 arm and 82 cases in the placebo one, with an efficacy of 52% during this interval. This indicates early protection by the vaccine, which appears from 12 days after the first dose. Although a previous SARS-CoV-2 infection represented an exclusion criterion from the study, some subjects with previous COVID-19 were enrolled (3,614/40,137; 9%). Including also these participants in the analysis, from 7 days after the second dose, nine cases of COVID-19 were observed among vaccine recipients and 169 among placebo recipients, achieving an efficacy of 94.6% (95% CI, 89.9–97.3).

Some more thorough data on the impact of vaccination with BNT162b1 (NCT04380701) on the humoral and adaptive cellular immune response have recently been made available and confirmed the data from the phase I/II studies (11). In this study, 60 participants were vaccinated with BNT162b1, 12 for each of the dose level groups (1, 10, 30, and 50 µg) received the first dose on day 1 and a booster dose on day 22 and 12 participants received only a 60 µg prime dose on day 1. The induction of high titers of anti-RBD antibodies was confirmed. At day 43 (21 days after dose II administration), the GMC of anti-RBD antibodies ranged from 3,920 to 18,289 U·ml⁻¹ among vaccinated, compared with a GMC of 602 U·ml⁻¹ in HCS. Among participants who had received only the first dose, the GMC of anti-RBD antibodies was 755 U·ml⁻¹, indicating the need of a booster to achieve a significant titer. Also, the

![Table 1](image-url)

| Vaccine | Dose (µg) | Age group (years) | Participants | Days after vaccine first dose | Titer IgG vaccinated | Ratio | Titer IgG HCS | Reference |
|---------|----------|------------------|--------------|-----------------------------|---------------------|-------|--------------|-----------|
|         | 36       |                  |              |                             | 5,033,017           | 36.23 |              |           |
|         | 43       |                  |              |                             | 1,305,996           | 9.40  |              |           |
|         | 57       |                  |              |                             | 1,183,066           | 8.52  |              |           |
|         | 9        | 119              | 9            |                             | 151,761             | 1.09  |              |           |
|         | 100 100 ≥71 | 10              | 1            |                             | 953                 | 0.01  |              |           |
|         | 15       |                  |              |                             | 84,383              | 0.61  |              |           |
|         | 29       |                  |              |                             | 203,365             | 1.46  |              |           |
|         | 36       |                  |              |                             | 2,636,979           | 18.98 |              |           |
|         | 43       |                  |              |                             | 8,091,439           | 58.25 |              |           |
|         | 57       |                  |              |                             | 3,638,522           | 26.20 |              |           |
|         | 119      | 18–55            | 15           |                             | 157,946             | 1.14  |              |           |
|         | 119      | 18–55            | 15           |                             | 131                 | 0.00  |              |           |
|         | 15       |                  |              |                             | 86,291              | 0.62  |              |           |
|         | 29       |                  |              |                             | 109,209             | 0.79  |              |           |
|         | 36       |                  |              |                             | 781,399             | 5.63  |              |           |
|         | 43       |                  |              |                             | 811,119             | 5.84  |              |           |
|         | 57       |                  |              |                             | 782,719             | 5.64  |              |           |
|         | 119      |                  |              |                             | 235,228             | 1.70  |              |           |

The ratio between the titer induced by the vaccine and the titer identified in the COVID-19 convalescent control population of the study is presented in the homonymous column.

*GMC RBD-binding IgG, Luminex assay (U mL⁻¹); †GMC S1-binding IgG, Luminex assay (U mL⁻¹); ‡not boosted; *IgG ELISA S-2P area under the curve IgG Williams mean; ♦GMC ELISA anti-S-2P; HCS, Human coronavirus disease 2019 (Covid-19) or SARS-CoV-2 infection convalescent serum; GMC geometric mean concentration.
| Vaccine     | Dose | Age group | Participants | Days after vaccine first dose | GMT neutralizing Abs | Ratio | GMT neutralizing Abs HCS | Reference |
|-------------|------|-----------|--------------|-----------------------------|----------------------|-------|-------------------------|-----------|
| BNT162b1*   | 10   | 19–54     | 12           | 7                           | 10                   | 0.11  | 94                      | (9)       |
|             |      |           |              |                              |                      |       |                         |           |
|             | 10   | 19–54     | 12           | 7                           | 10                   | 0.11  | 94                      | (9)       |
|             | 30   | 19–54     | 12           | 7                           | 10                   | 0.11  |                         |           |
|             | 100  | 19–54     | 12           | 7                           | 10                   | 0.11  |                         |           |
| BNT162b2*   | 10   | 18–55     | 12           | 21                          | 10                   | 0.11  | 94                      | (10)      |
|             |      |           |              |                              |                      |       |                         |           |
|             | 20   | 18–55     | 12           | 21                          | 10                   | 0.11  |                         |           |
|             | 30   | 18–55     | 12           | 21                          | 10                   | 0.11  |                         |           |
|             | 10   | 65–85     | 12           | 21                          | 10                   | 0.11  |                         |           |
| BNT162b1*   | 10   | 18–55     | 12           | 21                          | 10                   | 0.11  | 94                      | (11)      |
|             |      |           |              |                              |                      |       |                         |           |
|             | 20   | 18–55     | 12           | 21                          | 10                   | 0.11  |                         |           |
|             | 30   | 18–55     | 12           | 21                          | 10                   | 0.11  |                         |           |
|             | 10   | 65–85     | 12           | 21                          | 10                   | 0.11  |                         |           |
|             |      |           |              |                              |                      |       |                         |           |
|             | 20   | 65–85     | 12           | 21                          | 10                   | 0.11  |                         |           |
|             | 30   | 65–85     | 12           | 21                          | 10                   | 0.11  |                         |           |
|             | 10   | 65–85     | 12           | 21                          | 10                   | 0.11  |                         |           |
|             |      |           |              |                              |                      |       |                         |           |
|            | 20   | 65–85     | 12           | 21                          | 10                   | 0.11  |                         |           |
|             | 30   | 65–85     | 12           | 21                          | 10                   | 0.11  |                         |           |
|             | 10   | 65–85     | 12           | 21                          | 10                   | 0.11  |                         |           |
| BNT162b1*   | 1    | 20–56     | 12           | 8                           | 10                   | 0.11  | 94                      | (11)      |
|             |      |           |              |                              |                      |       |                         |           |
|             | 22   | 20–56     | 12           | 8                           | 10                   | 0.11  |                         |           |
|             | 29   | 20–56     | 12           | 8                           | 10                   | 0.11  |                         |           |
|             | 43   | 20–56     | 12           | 8                           | 10                   | 0.11  |                         |           |

(Continued)
TABLE 2  |  Continued

| Vaccine | Dose | Age group | Participants | Days after vaccine first dose | GMT neutralizing Abs | Ratio | GMT neutralizing Abs HCS | Reference |
|---------|------|-----------|--------------|-----------------------------|----------------------|-------|--------------------------|-----------|
| 10      | 20–56| 12        | 8            | 10                          | 0.11                 |       |                          |           |
|         |      |           | 22           | 21                          | 0.22                 |       |                          |           |
|         |      |           | 29           | 158                         | 1.68                 |       |                          |           |
|         |      |           | 43           | 126                         | 1.34                 |       |                          |           |
| 30      | 20–56| 12        | 8            | 10                          | 0.11                 |       |                          |           |
|         |      |           | 22           | 28                          | 0.30                 |       |                          |           |
|         |      |           | 29           | 308                         | 3.28                 |       |                          |           |
|         |      |           | 43           | 157                         | 1.67                 |       |                          |           |
| 50      | 20–56| 12        | 8            | 10                          | 0.11                 |       |                          |           |
|         |      |           | 22           | 32                          | 0.34                 |       |                          |           |
|         |      |           | 29           | 578                         | 6.15                 |       |                          |           |
|         |      |           | 43           | 333                         | 3.54                 |       |                          |           |
| 60      | 20–56| 12        | 8            | 10                          | 0.11                 |       |                          |           |
|         |      |           | 22           | 19                          | 0.20                 |       |                          |           |
|         |      |           | 29           | 20                          | 0.21                 |       |                          |           |
|         |      |           | 43           | 17                          | 0.18                 |       |                          |           |
| mRNA-1273† | 25 | 18–55    | 15           | 10                          | 0.23                 |       |                          | 43.1      |
|         |      |           | 15           | 10.9                        | 0.25                 |       |                          |           |
|         |      |           | 29           | 9                           | 0.23                 |       |                          |           |
|         |      |           | 36           | 53.1                        | 1.23                 |       |                          |           |
|         |      |           | 43           | 59.9                        | 1.39                 |       |                          |           |
|         |      |           | 57           | 39.1                        | 0.91                 |       |                          |           |
| 100     | 18–55| 15        | 1            | 10                          | 0.23                 |       |                          |           |
|         |      |           | 15           | 12.8                        | 0.30                 |       |                          |           |
|         |      |           | 29           | 10.2                        | 0.24                 |       |                          |           |
|         |      |           | 36           | 120.7                       | 2.80                 |       |                          |           |
|         |      |           | 43           | 153.8                       | 3.57                 |       |                          |           |
|         |      |           | 57           | 110.3                       | 2.56                 |       |                          |           |
| 250     | 18–55| 15        | 1            | 10                          | 0.23                 |       |                          |           |
|         |      |           | 15           | 13.4                        | 0.31                 |       |                          |           |
|         |      |           | 29           | 12.4                        | 0.29                 |       |                          |           |
|         |      |           | 36           | 158                         | 3.67                 |       |                          |           |
|         |      |           | 43           | 140.9                       | 3.27                 |       |                          |           |
|         |      |           | 57           | 120.8                       | 2.80                 |       |                          |           |
| mRNA-1273‡ | 25 | 56–70    | 10           | 1                           | –                    | –     |                          | 41        |
|         |      |           | 15           | –                           | –                    |       |                          |           |
|         |      |           | 29           | –                           | –                    |       |                          |           |
|         |      |           | 36           | 79                          | 1.93                 |       |                          |           |
|         |      |           | 43           | 116                         | 2.83                 |       |                          |           |
|         |      |           | 57           | 92                          | 2.24                 |       |                          |           |
| 25      | ≥71   | 10        | 1            | –                           | –                    | –     |                          |           |
|         |      |           | 15           | –                           | –                    |       |                          |           |
|         |      |           | 29           | –                           | –                    |       |                          |           |
|         |      |           | 36           | 121                         | 2.95                 |       |                          |           |
|         |      |           | 43           | 112                         | 2.73                 |       |                          |           |
|         |      |           | 57           | 88                          | 2.10                 |       |                          |           |
| 100     | 56–70| 10        | 1            | –                           | –                    | –     |                          |           |
|         |      |           | 15           | 11                          | 0.27                 |       |                          |           |
|         |      |           | 29           | –                           | –                    |       |                          |           |
|         |      |           | 36           | 289                         | 7.05                 |       |                          |           |

(Continued)
The ratio between the titer induced by the vaccine and the titer identified in the COVID-19 convalescent control population of the study is presented in the homonymous column.

*50% SARS-CoV-2-neutralizing GMTs; †Pseudovirus neutralization assay ID80 geometric mean; ‡Pseudotyped lentivirus reporter neutralization assay ID50; GMT, geometric mean titer; HCS, Human coronavirus disease 2019 (Covid-19) or SARS-CoV-2 infection convalescent serum.

### MRNA-1273 (MODERNA/NIH)

The second vaccine employing mRNA approved by the EMA, is mRNA-1273. mRNA-1273 is a lipid nanoparticle–encapsulated, nucleoside-modified messenger RNA-based vaccine that encodes the SARS-CoV-2 spike glycoprotein stabilized in its prefusion conformation. mRNA-1273 has been licensed for active immunization to prevent COVID-19 in individuals aged 18 years and older and it is administered as a course of 2 doses (0.5 mL each, containing 100 µg of messenger RNA embedded in SM-102 lipid nanoparticles), 28 days apart.

Preliminary results of immunogenicity were obtained in mouse model where two intramuscular injections with 0.01, 0.1, or 1 µg of mRNA-1273, 3 weeks apart, induced dose-dependent specific spike-binding antibodies after prime and boost in all mouse strains. Potent pseudovirus-neutralizing activity was elicited by 1 µg mRNA-1273, reaching reciprocal half-maximal inhibitory concentration (IC50) GMTs of 819 (BALB/c), 89 (C57BL/6J), and 1,115 (B6C3F1/J). Of note, neutralizing activity was conserved also against pseudoviruses expressing spike protein with the D614G substitution.

Interesting data were provided about the balance of T\(_{H1}\) and T\(_{H2}\) cells, the vaccination induced both IgG2a and IgG1 subclasses, indicating a equilibrated T\(_{H1}\)–T\(_{H2}\) response. After restimulation...
with a peptide pools covering the entire spike protein, splenocytes from immunized mice secreted more IFN-γ than IL-4, IL-5, or IL-13, suggesting a Th1-dominated response. This Th1-oriented response was confirmed also by the evaluation of intracellular cytokines in CD4+ T cells re-stimulated with spike peptide pools 7 weeks after immunization. Overall, immunization with mRNA-1273 elicits balanced Th1 and Th2 responses in mice, with a dose-dependent protection from viral replication and immunopathology in nose and lung of mice (24).

These results were confirmed also in nonhuman primate models which were immunized with 10 or 100 µg of mRNA-1273. The vaccination induced antibody levels exceeding those in HCS, with live-virus reciprocal 50% inhibitory dilution GMT of 501 in the 10-µg dose group and 3,481 in the 100-µg dose group. Vaccination induced Th1-biased (interferon-γ, interleukin-2, or tumor necrosis factor α) CD4+ T-cell responses and low or undetectable Th2 (interleukin-4 or 13) or CD8+ T-cell responses. Viral replication was not detectable in bronchoalveolar lavage fluid by day 2 after challenge in seven of eight animals in both vaccinated groups. No viral replication was detectable in the nose of any of the eight animals in the 100 µg dose group by day 2 after challenge, and limited inflammation or detectable viral genome or antigen was noted in lungs of animals in either vaccine group (25).

In two publications of phase I study (NCT04283461), mRNA-1273 was administered twice at doses of 25, 100, and 250 µg 28 days apart in 45 healthy adults, 18–55 years of age (12), and in 40 healthy adults over 56 years of age at doses of 25 and 100 µg (13). On day 57 from the prime dose of 100 µg, the GMT of specific anti-RBD antibodies induced by vaccination was 782,719 for subjects aged 18–55 years, 1,183,866 for subjects aged between 56 and 70 years and 3,638,522 for subjects over the age of 70 (12, 13). Apparently, older age groups did not show lower values of anti-RBD antibodies compared to younger groups. All these values were far superior to those recorded in HCS. After the second dose, the neutralizing activity of serum was assessed by different methods in all participants, obtaining values generally similar to those in the upper half of the distribution in HCS (12). Interestingly, a correlation was observed between the anti-RBD antibody titer and the neutralizing activity of the serum. Regarding the cellular T response, CD4+ T lymphocytes under stimulation of a pool of spike-specific peptides were strongly oriented toward the expression of Th1 cytokines (tumor necrosis factor α > interleukin-2 > interferon γ), with a minimal production of Th2 cytokines (interleukin-4 and interleukin-13). In contrast, a low level CD8+ T lymphocytes response was detected only in the 100 µg dose group (12). In a later letter, data about immunogenicity 90 days after the second dose in 34 participants of the above studies, who received two injections of vaccine at a dose of 100 µg, were provided. Overall, despite a slight decline, both binding and NA values exceeded those observed among HCS in all age groups (14).

Recently, the results of the randomized and controlled phase III study (NCT04470427) have been published. The study assessed mRNA-1273 at a dose of 100 µg, administered twice 28 days apart, for the prevention of COVID-19 (26). A total of 30,420 participants were enrolled, of which 2.2% had a serologic or virologic data at enrolment compatible with previous COVID-19. Among participants who had received placebo, 185 cases of COVID-19 were documented, vs. 11 observed in participants who had received mRNA-1273, suggesting a vaccine efficacy of 94.1% (95% CI, 89.3–96.8). The efficacy of the vaccine was also confirmed in subgroups of participants such as those with previous COVID-19, or those older than 65 years.

**THE SPECIAL POPULATIONS**

A widely heterogeneous group, immunocompromised patients can overall be regarded as a population of special interest for vaccine programs, as they may be at higher risk for COVID-19 than the general population (27) but, however, may not respond as well to the vaccine due to several alterations of the physiologic immune response (28). Data is not currently available to establish vaccine safety and efficacy of the approved vaccines in these groups.

**People Living With HIV**

Despite data remaining limited, people living with HIV (PLHIV) infection were included in mRNA COVID-19 vaccine clinical trials. In the NCT04368728 trial (10), a total 121 PLHIV (0.3%) were included, 59 receiving BNT162b2 and 62 receiving placebo. In the NCT04470427 trial (23), a total 179 PLHIV (0.6%) were included at baseline, 87 in the mRNA-1273 arm and 92 in the placebo arm. In both instances, the studies do not report safety and efficacy data for this subset nor immunologic details.

**Solid Organ, Hematopoietic Stem-Cells Transplant Recipients and Malignancies**

Recipient of solid organ, hematopoietic stem cell transplant and patients with active malignancies were excluded from the COVID-19 mRNA vaccine trials (10, 12). Therefore, there are no published data on the immunogenicity and interaction of mRNA-based antiviral vaccines with antineoplastic therapies. In the NCT04368728 trial, 733 patients in the BNT162b2 arm (3.9%) had a history of malignant disease, particularly 12 patients a history of leukemia (0.1%), 22 of lymphoma (0.1%), and 4 (0%) of metastatic solid tumor (10). Similar, patients with active oncolgical conditions have been excluded in the NCT04283461 trial. Thus, currently data on safety and efficacy of COVID-19 mRNA vaccines could only be inferred to these populations. Diverse approaches to mRNA-based vaccines, with therapeutic purpose, for patients with active malignancies have been employed in the last 10 years, without major concerns regarding safety (15, 29). On the other hand, data on the efficacy of mRNA-based COVID-19 vaccines lacks for immune-compromised hosts, a population with a background of suboptimal humoral and cellular responses to vaccinations (30).

**Individuals Receiving Immunosuppressing Drugs for Autoimmune Disorders**

As for antineoplastic therapies, there is no data on the immunogenicity and interaction of mRNA-based antiviral vaccines with disease-modifying immunosuppressing...
drugs for autoimmune disorders. One-hundred eighteen patients with rheumatic diseases were included in the NCT04470427 trial (10), 62 receiving BNT162b2 (0.3%) and 56 receiving placebo (0.3%). No data on baseline treatments, safety and immunogenicity of mRNA vaccine is reported for this subcategory (10). Concerns regard the theoretical risk of disease flare after vaccination, in particular development of autoimmune syndromes related to type I interferon response stimulated by an mRNA/DNA vaccine (15), with specific concern of a SARS-CoV-2 antibody-mediated immune enhancement and a systemic inflammatory response.

**VACCINE-ENHANCED DISEASE**

Data from the study of SARS-CoV and other respiratory viruses suggests that anti-SARS-CoV-2 antibodies could exacerbate COVID-19, in the so called vaccine-enhanced disease (31), which can be linked to antibody-dependent enhancement (ADE) and vaccine-associated enhanced respiratory disease (VAERD) (32). ADE is an Fc–mediated enhancement of infection, with macrophage activation and cytokines secretion, typically associated with flaviviruses (33). VAERD is a distinct clinical syndrome, related to the production of an excessive amount of non-neutralizing antibodies, consequently to a T_{H}2 biased immune response, which could potentially result in immune complex deposition and complement activation (32). Currently no evidence of ADE or VAERD occurrence among vaccinated individuals has been provided for SARS-CoV-2. Zhou et al. (34) showed in a convalescent individual with potent IgG neutralizing activity, that ADE is correlated to antibodies against specific non-overlapping epitopes of RBD. All the above-mentioned studies showed the production of relevant amount of NA, making VAERD unlikely. Moreover, data from mice (24) and humans (12), illustrated how immune response after vaccination is oriented toward a T_{H}1 phenotype for both BNT162b1 (11) and mRNA-1273 (12).

**DISCUSSION**

Overall, the currently approved mRNA-based vaccines against COVID-19 displayed a reassuring safety and efficacy profile, with the latter above 94%. They can elicit specific antibodies titers and NA concentrations that are far superior from those observed among HCS, across a wide span of age. Moreover, the vaccine-induced T cellular response is oriented toward a T_{H}1 response and no evidence of vaccine-enhance disease have been reported. Finally, initial evidence is showing, at least for BNT162b2, that vaccine efficacy is not hampered by mutations of SARS-CoV-2 spike protein, like those characterizing the UK and SA variants. These results are encouraging considering the enormous number of individuals receiving immunization. More data is eagerly awaited about the duration of specific and NA alongside with more detailed immunologic descriptions of humoral and cellular immunity, particularly in those with a previous COVID-19 infection or immunocompromised. Moreover, it is mandatory to quickly define the effectiveness of those vaccines against other viral variants and the role exerted in selecting them.

**SUMMARY**

Preliminary data shows how BNT162b2 and mRNA-1273 can elicit specific antibodies titers and neutralizing antibodies concentrations above those observed among COVID-19 human convalescent serum in the first 100 days after vaccination.

**AUTHOR CONTRIBUTIONS**

AL, AB, and AG conceived the study. AL wrote the first version of the manuscript. All the authors revised the final version of the manuscript.

**FUNDING**

This work is part of the END-COVID project, co-funded by Fondo di Beneficenza Intesa San Paolo.

**REFERENCES**

1. World Health Organization (WHO). COVID-19 Weekly Epidemiological Update. (2020). Available online at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20201012-weekly-epi-update-9.pdf
2. McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. (2020) 590:630–40. doi: 10.1038/s41586-020-03041-6
3. Marsden BD, Cox S, James T, Warren F, Peck LJ, Ritter TG, et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. N Engl J Med. (2020) 1-8.
4. Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzenlin LC, Rattigan SM, et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nat Commun. (2020) 11:1-16. doi: 10.1038/s41467-020-18450-4
5. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. (2020) 584:457–62. doi: 10.1038/s41586-020-2550-z
6. Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. (2020) 5:1598–607. doi: 10.1038/s41564-020-00813-8
7. Lau EHY, Tsang OTY, Hui DSC, Kwan MYW, Chan W hung, Chiu SS, et al. Neutralizing antibody titres in SARS-CoV-2 infections. Nat Commun. (2021) 12:1–7. doi: 10.1038/s41467-020-20247-4
8. Krammer F. SARS-CoV-2 vaccines in development. Nature. (2020) 586:516–27. doi: 10.1038/s41586-020-2798-3
9. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. (2020) 586:589–93. doi: 10.1038/s41586-020-2639-4
10. Walsh EE, French RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. (2020) 383:2439–50. doi: 10.1056/NEJMoa 2027906
11. Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. (2020) 586:594–9. doi: 10.1038/s41586-020-2814-7
In an era of rapid vaccine development, mRNA vaccines offer a promising approach to combating the COVID-19 pandemic. These vaccines leverage messenger RNA (mRNA) technology to instruct the body to produce specific antigens that elicit an immune response. This approach has been particularly successful with the development of vaccines like Pfizer-BioNTech's Comirnaty and Moderna's COVID-19 vaccine.

The European Medicines Agency (EMA) has played a crucial role in the authorization and regulatory oversight of these vaccines in the European Union. The EMA’s recommendations have been instrumental in ensuring the safety and efficacy of these vaccines, thereby facilitating their widespread use.

In the context of this article, we observe the critical roles of mRNA vaccines in the global vaccination strategy, emphasizing their importance in the fight against COVID-19. The EMA’s role in regulating these vaccines is highlighted, underscoring the regulatory framework’s significance in ensuring vaccine safety and efficacy.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Lombardi, Bocci, Ungaro, Villa, Castelli, Mangioni, Muscatello, Gori and Bandera. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.